Good MorningEquity markets retreated for the 3rd day on Wednesday as investors weighed details from the FOMC minutes. The minutes reveal a Fed uneasy about cutting interest rates because of the inflation risk. Economic activity is steady and on track for a soft landing; easing up on rates too soon would reinvigorate activity and inflation. In that scenario, the FOMC would have to hike rates again soon and possibly keep them there indefinitely. As it is, higher for longer may mean longer than the market is pricing.
Earnings from tech giant NVIDIA will be the driving force for market activity on Thursday. The risk is expectations. In the last twelve months, the market has pushed NVIDIA's share price up 360% on ramping AI activity and may have outrun reality. Even with a blowout report, the market is overbought, and the trade is crowded, setting it up for correction. Without NVIDIA and big tech to drive it, the S&P 500 may have nowhere to go but lower. Featured: Trump goes "all-in" on Grand Canyon energy breakthrough (Ad) 
|
Technology | |
Ahead of its upcoming earnings report on February 29, Dell Technologies (NYSE: DELL) just broke out of a lengthy consolidation. Year-to-date, the technology and computer giant is now up almost 15% and a whopping 109% over the previous year.
The company has recently received several favorable anal... Read the Full Story |
|
From Our Partners | | Barrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourmile, Goldrush, and Cortez Hills, a region that could hold as much as 60 million ounces of gold.
Bordering Fourmile and less than a mile from Goldrush sits a little-known explorer now moving from historical data toward active exploration, setting targets and preparing for a maiden drilling program.
With gold trading near record highs, this could be a pivotal stage for an overlooked name in the district. | | See why this overlooked gold explorer could be entering its most important stage |
|
Consumer Staples | |
Keurig Dr Pepper's (NASDAQ: KDP) share price fell following the Q4 results and guidance for 2024, setting up the next buying opportunity. The market is down but aligning with a bottoming pattern while the business reaches an inflection point. Coffee remains a weak spot, and the guidance isn’... Read the Full Story |
|
Communication Services | |
After a lackluster second half to 2023, shares of The Trade Desk, Inc. (NASDAQ: TTD) are once again doing what they love best: rallying. Truth be told, it was starting to look like they were forming a downtrend, having fallen more than 30% from last summer’s peak into January. But with equit... Read the Full Story |
|
From Our Partners | | More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily volume over 500,000 shares, and over $10 million in trailing revenue.
Only five stocks cleared every filter, spanning five different sectors. Two are profitable today, and one pays a substantial dividend.
The report also flags what could go wrong with each pick, including dilution and convertible debt. | | See the five stocks that survived this strict revenue screen |
|
Consumer Staples | |
"Buy low, sell high" is the most common investing mantra, but it's easier said than done. Instead of trying to time the market and profit from volatility, many investors fill their portfolios with low-beta stocks. What are low-beta stocks?
To understand how to build a low-beta portfolio, you'll ... Read the Full Story |
|
Communication Services | |
The 30% drop from their pre-earnings share price should tell you everything you need to know about Roku, Inc.’s (NASDAQ: ROKU) earnings report. The streaming giant reported their Q4 numbers last week, and while they managed to deliver a beat on revenue and shared decent forward guidance, inv... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Consumer Discretionary | |
Rivian’s (NASDAQ: RIVN) Q4 release further proves that the EV market bubble has burst. Internal metrics and guidance suggest demand has peaked and current capacity is too much. The takeaway is that business isn’t getting any better soon; if Rivian can’t start producing profits, i... Read the Full Story |
|
Technology | |
While shares of Advanced Micro Devices (NASDAQ: AMD) might not grab the headlines as much as its competitor, Nvidia (NASDAQ: NVDA), shareholders of the global semiconductor company are undoubtedly happy campers.
Thanks to a significantly higher gap in the pre-market this morning, shares of AMD a... Read the Full Story |
|
Technology | |
Traders and investors fearing an NVIDIA (NASDAQ: NVDA)-led market correction can put those fears to rest. The company’s Q4 results reveal that the AI market is still strong, stronger than expected and accelerating. The results can be described as nothing but a blowout on top of four quarters... Read the Full Story |
|
Technology | |
Achieving risk-free passive income from the stock market is the dream of investors. Unfortunately, nothing in the stock market are risk-free. However, if you are willing to have a cap on your downside in exchange for a cap on the upside, there is a multi-leg options strategy worth considering call... Read the Full Story |
|
Industrials | |
Amprius Technologies (NYSE: AMPX) is an emerging lithium-ion battery disruptor. The company’s silicon anode design provides greater density, quicker charge time, and higher discharge rates, making them a perfect fit for virtually any application. The company is ramping up production as quick... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. | | View Today's Stock Pick |
|
